NDAORALTABLET
Approved
Nov 2020
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Drug data last refreshed 6h ago · AI intelligence enriched 9h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SUTAB is an oral tablet formulation of sodium sulfate, magnesium sulfate, and potassium chloride—a bowel preparation electrolyte solution. It is indicated for cleansing the colon prior to colonoscopy or other GI procedures. The drug works by osmotic action to evacuate the bowel without significant systemic electrolyte absorption.
$29MPart D
Peak11.0 years to LOEProduct is at peak lifecycle with $29M in Part D spending, suggesting established market presence and stable commercial team supporting a mature branded bowel prep category.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SUTAB positions you in a mature, stable branded pharmaceutical with strong Part D presence and long patent protection, ideal for commercial sales, marketing, and brand management professionals. The product offers steady-state career roles without significant new indication or launch complexity, suited for professionals seeking stable, established portfolio management.
Brand Manager
Worked on SUTAB at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.